R0V.F REVENIO GROUP CORP. EO 15
- Market cap
- EUR 421M
- P/E
- 24.4x
- P/B
- 2.81x
- ROE
- 4.1%
- Dividend yield
- 2.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is R0V.F undervalued?
Graham numberR0V.F trades 74.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
REVENIO GROUP CORP. EO 15 fundamental analysis
No fundamental analysis for REVENIO GROUP CORP. EO 15 yet.
REVENIO GROUP CORP. EO 15 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About REVENIO GROUP CORP. EO 15
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or eme…
Full company profileREVENIO GROUP CORP. EO 15 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
REVENIO GROUP CORP. EO 15 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 97.0M | 96.6M | 104M | 110M | 133M |
| Gross Profit | 69.8M | 68.2M | 72.9M | 77.8M | 88.2M |
| Operating Income | 29.7M | 26.3M | 25.1M | 25.4M | 9.40M |
| EBITDA | 32.8M | 30.1M | 30.5M | 27.7M | 15.4M |
| Net Income | 21.8M | 19.1M | 18.5M | 17.4M | 6.20M |
| EPS | 0.82 | 0.72 | 0.70 | 0.65 | 0.18 |
| Balance Sheet | |||||
| Total Assets | 136M | 137M | 141M | 151M | 479M |
| Total Liabilities | 45.2M | 37.5M | 33.6M | 35.9M | 330M |
| Shareholders' Equity | 90.9M | 99.9M | 108M | 115M | 150M |
| Cash & Short-term Investments | 32.1M | 21.5M | 20.7M | 26.2M | 17.8M |
| Cash Flow | |||||
| Operating Cash Flow | 23.2M | 10.9M | 23.9M | 30.2M | -11.6M |
| Capital Expenditure | 2.00M | 4.08M | 4.20M | 4.18M | 5.60M |
| Free Cash Flow | 21.2M | 6.79M | 19.7M | 26.1M | -17.2M |
| Ratios | |||||
| ROE | 23.9% | 19.1% | 17.2% | 15.2% | 4.1% |
| ROA | 16.0% | 13.9% | 13.1% | 11.6% | 1.3% |
| Net Profit Margin | 22.4% | 19.8% | 17.9% | 15.9% | 4.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
REVENIO GROUP CORP. EO 15 dividends
- Dividend yield
- 2.53%
- Forward dividend
- -
- Payout ratio
- 61.1%
- Ex-dividend date
- Apr 11, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 10.6M | 0.40 | 61.1% |
| 2024 | EUR 10.1M | 0.38 | 54.6% |
| 2023 | EUR 9.57M | 0.36 | 50.1% |
| 2022 | EUR 9.04M | 0.34 | 41.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns REVENIO GROUP CORP. EO 15
- Insiders 6.71%
- Institutions 44.27%
- Public & others 49.02%
- Shares outstanding 42.1M
- Free float 28.6M
REVENIO GROUP CORP. EO 15 company profile
- Company name
- REVENIO GROUP CORP. EO 15
- Ticker
- R0V.F
- ISIN
- FI0009010912
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 765
- Fiscal year end
- December
- Address
- Härkähaankuja 7, Vantaa, Finland, 01730
- Phone
- 358 9 8775 1150
- Website
- reveniogroup.fi
About REVENIO GROUP CORP. EO 15
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
REVENIO GROUP CORP. EO 15 management
6- Mr. Jouni Toijala B.Sc., M.B.A.President & CEO · born 1968
- Mr. Jukka Kainulainen M.Sc.Chief Financial Officer · born 1982
- Mr. Ari IsomäkiVice President of Operations · born 1966
- Mr. John FloydVice President of Sales · born 1970
- Ms. Hanna VuornosVice President of People & Culture · born 1978
- Mr. Umberto BargiggiaVice President of International Sales · born 1982